Windward Bio’s WIN378 Delivers Positive Phase 2 Asthma Data as Twice-Yearly Anti-TSLP Antibody Moves Into Phase 3
Windward Bio has reported positive interim Phase 2 results for WIN378, also known as HBM9378 or SKB378, showing sustained improvements in lung function and key inflammatory biomarkers after a single dose in patients with uncontrolled asthma. With a…
Kelun-Biotech’s TROP2 ADC Sac-TMT Shows Durable Activity Across Genomically Altered NSCLC in a Phase 2 Study
Sichuan Kelun-Biotech has reported new Phase 2 data for its TROP2-directed antibody-drug conjugate sacituzumab tirumotecan (sac-TMT; SKB264/MK-2870) in heavily pretreated non-small cell lung cancer (NSCLC), showing durable antitumor activity across…
Kelun Biotech seeks marketing approval on sac-TMT for the first-line treatment of PD-L1-negative TNBC
On July 30, 2026, Sichuan Kelun Biotech Co., Ltd. (“Kelun”) announced that its independently developed antibody-drug conjugate (ADC) targeting human trophoblast surface antigen 2 (TROP2), sac-TMT (also known as SKB264/MK-2870) (Gitalay®), has…